|D003141||Communicable Diseases NIH||0.07|
There is one clinical trial.
The current sars-cov-2 epidemic is responsible for severe respiratory infections leading to end-of-life situations. Dexmedetomidine may be indicated in mild to moderate sedation in palliative patients, due to its pharmacological characteristics. The hypothesis of this study is that Dexmedetomidine would allow effective and safe light sedation in patients with respiratory failure in palliative situations suffering from Covid-19 infection.
Description: Number of days of mild to moderate sedation induced by dexmedetomidine until death or change of molecule.Measure: Efficacy of mild to moderate palliative sedation induced by Dexmedetomidine. Time: Day 30
Description: Overall survival time in days from inclusion.Measure: Overall survival of patients on Dexmedetomidine Time: Day 30
Description: The daily effectiveness of Dexmedetomidine on pain assessed by the NCS-R scale (Nociception Coma Scale) : the score is between 0 and 9.Measure: Daily analgesic effect of Dexmedetomidine Time: Day 30
Description: Number of the various sedative molecules used in the subjects of the study in addition to Dexmedetomidine.Measure: Other sedative pharmacological agents Time: Day 30
Description: Daily dosage measurement in ug / kg / h of Dexmedetomidine necessary to obtain light to moderate sedationMeasure: Average dosage required for Dexmedetomidine to achieve mild to moderate sedation Time: Day 30
Data processed on January 01, 2021.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.Drug Reports MeSH Reports HPO Reports